Toby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD

Articles by Toby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD

Dr. Eyre on the Design of the BRUIN-MCL-321 Trial in MCL

ByToby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD

June 10th 2022

Toby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, discusses the design and the rationale of the phase 3 BRUIN-MCL-321 trial in mantle cell lymphoma.

Dr. Eyre on BTK Inhibitors in Combination With Venetoclax for MCL

ByToby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD

September 7th 2018

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses the potential for BTK inhibitors to be used in combination with venetoclax for mantle cell lymphoma.

Dr. Eyre on Results of Venetoclax in Relapsed/Refractory MCL

ByToby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD

August 8th 2018

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses the results of single-agent venetoclax (Venclexta) in patients with relapsed/refractory mantle cell lymphoma.

Dr. Eyre Discusses Venetoclax Monotherapy in MCL

ByToby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD

July 9th 2018

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Foundation Trust, discusses venetoclax (Venclexta) monotherapy in patients with mantle cell lymphoma.